News for Arvinas, Inc. (ARVN)

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the U.S. […]

The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Key Highlights: Arvinas Inc. (ARVN) reports successful results from the Phase 3 VERITAC-2 trial in breast cancer treatment. Analysts' average price target fo

”“ Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicati

**media[585923]**

**media[578175]**

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

Arvinas (ARVN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a look at where Arvinas, Inc.

The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Novo Nordisk, Roche, Pfizer, Arvinas and J&J are part of the Zacks top Analyst Blog.

Arvinas’ cash burn and lack of pipeline candidates hurt its outlook. See why ARVN stock is a sell, despite a healthy cash balance, after the failed trial.

Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with Pfizer (PFE). Read more here.

U.S. stocks traded lower midway through trading, with the Dow Jones falling more than 1% on Tuesday. The Dow traded down 1.07% to 41,462.06 while the NASDAQ de...

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded ...

Massachusetts-based 2seventy bio, Inc. (TSVT), a cell and gene therapy company is up over 76 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.